A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria
- PMID: 6354507
- PMCID: PMC2536154
A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria
Abstract
A total of 99 male Zambian patients with symptomatic falciparum malaria were treated in a double-blind randomized manner with either mefloquine (1000 mg given in one day) or chloroquine (1500 mg given over 3 days). An S-type response was seen in all the chloroquine patients and 98% of the mefloquine group; one patient in the latter group (2%) showed an RI-type response, but the parasites obtained during the recrudescence were sensitive to both chloroquine and mefloquine in the in vitro microtest, and the patient responded satisfactorily to oral chloroquine. The rate of clearance of parasitaemia was marginally faster in the chloroquine-treated group. The rate of clearance of fever was similar in the two groups. Both drugs were well tolerated and side-effects such as nausea, vomiting, dizziness, loose stools, and pruritus were mild and transient. Pruritus was more common after chloroquine administration and dizziness more common in the mefloquine group. There were no drug-induced alterations in the haematological and biochemical profiles.
Similar articles
-
A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria.Bull World Health Organ. 1987;65(3):369-73. Bull World Health Organ. 1987. PMID: 3311440 Free PMC article. Clinical Trial.
-
A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.Bull World Health Organ. 1983;61(2):299-305. Bull World Health Organ. 1983. PMID: 6345013 Free PMC article. Clinical Trial.
-
A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria.Bull World Health Organ. 1985;63(2):339-43. Bull World Health Organ. 1985. PMID: 3893778 Free PMC article. Clinical Trial.
-
A Review of Modifications of Quinoline Antimalarials: Mefloquine and (hydroxy)Chloroquine.Molecules. 2022 Feb 2;27(3):1003. doi: 10.3390/molecules27031003. Molecules. 2022. PMID: 35164267 Free PMC article. Review.
-
Chloroquine: novel uses & manifestations.Indian J Med Res. 2008 Apr;127(4):305-16. Indian J Med Res. 2008. PMID: 18577785 Review.
Cited by
-
Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.Bull World Health Organ. 1995;73(5):631-42. Bull World Health Organ. 1995. PMID: 8846489 Free PMC article. Clinical Trial.
-
New antimalarials. A risk-benefit analysis.Drug Saf. 1995 Apr;12(4):264-73. doi: 10.2165/00002018-199512040-00006. Drug Saf. 1995. PMID: 7646825 Review.
-
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.PLoS One. 2017 Feb 13;12(2):e0168780. doi: 10.1371/journal.pone.0168780. eCollection 2017. PLoS One. 2017. PMID: 28192434 Free PMC article.
-
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.Malar J. 2016 Sep 13;15(1):469. doi: 10.1186/s12936-016-1511-3. Malar J. 2016. PMID: 27624471 Free PMC article. Clinical Trial.
-
Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.Wellcome Open Res. 2017 Jun 2;2:13. doi: 10.12688/wellcomeopenres.10658.2. eCollection 2017. Wellcome Open Res. 2017. PMID: 28630942 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical